Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg)

Background: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-06, Vol.11 (12), p.3544
Main Authors: Fernández-Salazar, Luis, Campillo, Ana, Rodrigo, Luis, Pérez-Aisa, Ángeles, González-Santiago, Jesús M, Xavier Segarra Ortega, Denkovski, Maja, Natasa Brglez Jurecic, Bujanda, Luis, Gómez Rodríguez, Blas José, Ortuño, Juan, Georgopoulos, Sotirios, Jonaitis, Laimas, Puig, Ignasi, Nyssen, Olga P, Megraud, Francis, Colm O’Morain, Gisbert, Javier P
Format: Article
Language:English
Subjects:
Antibiotics
Clinical medicine
Compliance
Drug dosages
Failure
Gastric cancer
Infections
Patients
Penicillin
Success
Ulcers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results. Methods: An international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult cases treated with HDDT were registered at e-CRF AEG-REDCap platform until June 2021. Sixty patients were prescribed with HDDT (98% compliance), 19 of them received a first-line therapy and 41 a rescue treatment (second- to sixth-line). Results: Overall HDDT effectiveness was 52% (per-protocol) and 51% (modified intention-to-treat). First-line and rescue treatment lines were equally effective, but the effectiveness was worse when patients had previously received metronidazole, tetracycline, or rifabutin. Adding bismuth to HDDT in rescue treatment did not yield better results. The incidence of adverse events was 30%, diarrhea being the most common (20% of patients); no serious adverse events were reported. Conclusion: Although HDDT is safe and has good compliance, it is not a good option in European first-line or rescue H. pylori treatment, even when adding bismuth.
ISSN:2077-0383
DOI:10.3390/jcm11123544